ALKS Alkermes Plc

Alkermes to Present at Goldman Sachs 38th Annual Global Healthcare Conference

DUBLIN--(BUSINESS WIRE)--

Alkermes plc (NASDAQ: ALKS) announced today that its Chief Executive Officer, Richard Pops, will participate in a fireside chat at the Goldman Sachs 38th Annual Global Healthcare Conference on Thursday, June 15, 2017 at 8:40 a.m. PT (11:40 a.m. ET/4:40 p.m. BST) from Rancho Palos Verdes, Calif. The audio portion of the fireside chat may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.

EN
08/06/2017

Underlying

ALKSAlkermes Plc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Alkermes Plc

EUR 154.33
ALKS ALKERMES PLC

Moody's Ratings assigns Ba2 CFR to Alkermes; outlook stable

Moody's Ratings  (Moody's) assigned ratings to Alkermes, Inc. ("Alkermes"), including a Ba2 Corporate Family Rating (CFR), Ba2-PD Probability of Default Rating (PDR). Concurrently, we assigned Ba2 ratings to the senior secured bank credit facilities comprised of term loan A due 2031 and term loan B ...

4h / 53m 4h / 53m 1 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 42.87
AMN AMN Healthcare ...
XEL Xcel Energy Inc... ... (+29)

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

AMN AMN HEALTHCARE SERVICES INC.
XEL XCEL ENERGY INC.
SGRY SURGERY PARTNERS INC.
SGMO SANGAMO THERAPEUTICS INC.
PLOW DOUGLAS DYNAMICS INC.
NWL NEWELL BRANDS INC
MCD MCDONALD'S CORPORATION
LAD LITHIA MOTORS INC. CLASS A
HAS HASBRO INC.
GTY GETTY REALTY CORP.
CLX CLOROX COMPANY
APD AIR PRODUCTS AND CHEMICALS INC.
ANGO ANGIODYNAMICS INC.
ALKS ALKERMES PLC
LBRDA LIBERTY BROADBAND CORP. CLASS A
MAT MATTEL INC.
UHT UNIVERSAL HEALTH REALTY INCOME TRUST
VFC V.F. CORPORATION
FLGT FULGENT GENETICS
PFE PFIZER INC.
CWEN CLEARWAY ENERGY INC. CLASS C
PEAK HEALTHPEAK PROPERTIES INC.
LSTR ELECTROSTAR S.A.
MTCH MATCH GROUP INC.
HRMY HARMONY BIOSCIENCES HOLDINGS
BALY BALLYS CORPORATION
SHYF THE SHYFT GROUP INC
NWM NORWEST MINERALS
DOUG DOUGLAS ELLIMAN INC
08/08/24 August 8, 2024 1 EN
EUR 214.35
ALKS ALKERMES PLC

Alkermes, Inc.: Update to credit analysis

Alkermes credit profile reflects its modest financial leverage and strong liquidity, offset by revenue concentration in three neuroscience-based products and approaching generic competition.

03/04/24 March 4, 2024 1 EN
EUR 154.33
ALKS ALKERMES PLC

Moody's affirms Alkermes' Ba3 CFR, outlook stable

Moody's Investors Service ("Moody's") affirmed the ratings of Alkermes, Inc., a subsidiary of Alkermes plc (collectively "Alkermes"). The affirmed ratings include the Ba3 Corporate Family Rating, the Ba3-PD Probability of Default Rating, and the Ba3 senior secured term loan rating. There is no chang...

02/28/24 February 28, 2024 1 EN
EUR 214.35
ALKS ALKERMES PLC

Alkermes, Inc.: Update to credit analysis

Our credit view of Alkermes reflects its good growth prospects on core products including Vivitrol, Aristada, and Lybalvi constrained by its pipeline execution and commercialization risk.

03/03/23 March 3, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch